Beth Marsh will lead commercialization for Neurotech, which gained FDA approval for its eye disease therapy. Neurotech in May ...

RBC Capital lowered the firm’s price target on Apellis (APLS) to $21 from $24 and keeps a Sector Perform rating on the shares. The firm has ...

Pharmaceuticals announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

Detailed price information for Mural Oncology Plc (MURA-Q) from The Globe and Mail including charting and trades.

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition. | After ...

BioHarvest Sciences Inc. BHST shares ended the last trading session 5.2% higher at $5.90. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Biotech leaders urge Senate intervention as FDA restructuring risks expertise loss impacting operations. Read more here.

US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing ...

The FDA has granted Priority Review to pegcetacoplan for the treatment of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.